초록 ▼

The application relates to a Yersinia pseudotuberculosis cell, which comprises nucleic acid coding for expression of at least one Yersinia pestis Caf1 polypeptide or of at least one antigenic fragment of Yersinia pestis Caf1, more particularly to an attenuated Y. pseudotuberculosis cell, which expre

The application relates to a Yersinia pseudotuberculosis cell, which comprises nucleic acid coding for expression of at least one Yersinia pestis Caf1 polypeptide or of at least one antigenic fragment of Yersinia pestis Caf1, more particularly to an attenuated Y. pseudotuberculosis cell, which expresses the Y. pestis capsule. Said Y. pseudotuberculosis cell is exceptionally efficient in protecting against both bubonic plague and pulmonary plague.

대표청구항 ▼

1. A genetically attenuated Yersinia pseudotuberculosis cell, wherein one or more genes selected from HPI, yopK and psaA are deleted or inactivated, and wherein nucleic acid coding for expression of at least one Yersinia pestis Caf1 polypeptide at the surface of said Y. pseudotuberculosis cell is in

1. A genetically attenuated Yersinia pseudotuberculosis cell, wherein one or more genes selected from HPI, yopK and psaA are deleted or inactivated, and wherein nucleic acid coding for expression of at least one Yersinia pestis Caf1 polypeptide at the surface of said Y. pseudotuberculosis cell is integrated into the chromosome of said Y. pseudotuberculosis cell. 2. The genetically attenuated Y. pseudotuberculosis cell of claim 1, which is a live cell or a killed cell. 3. The genetically attenuated Y. pseudotuberculosis cell of claim 2, which expresses said at least one surface-expressed Y. pestis Caf1 in oligomeric form. 4. The genetically attenuated Y. pseudotuberculosis cell of claim 1, which expresses the Y. pestis F1 protein at its surface. 5. The genetically attenuated Y. pseudotuberculosis cell of claim 1, which is surrounded by a Y. pestis capsule. 6. The genetically attenuated Yersinia pseudotuberculosis cell of claim 1, which derives from a cell of the Y. pseudotuberculosis IP 32953 strain, the chromosomal sequence of which is the sequence available under accession number NC—006155, by: deletion or inactivation of one or more genes selected from HPI, yopK and psaA, and bychromosomal insertion of nucleic acid coding for expression of at least one Yersinia pestis Caf1 polypeptide at the surface of said Y. pseudotuberculosis cell. 7. The genetically attenuated Yersinia pseudotuberculosis cell of claim 1, wherein at least one transposon carrying the caf operon is integrated in the chromosome of said Y. pseudotuberculosis cell. 8. A genetically attenuated Yersinia pseudotuberculosis strain, wherein one or more genes selected from HPI, yopK and psaA are deleted or inactivated, and wherein nucleic acid coding for expression of at least one Yersinia pestis Caf1 polypeptide at the surface of said Y. pseudotuberculosis cell is integrated into the chromosome of said Y. pseudotuberculosis cell. 9-12. (canceled) 13. An immunogenic composition or vaccine, which comprises at least one genetically attenuated Yersinia pseudotuberculosis cell of claim 1. 14. The immunogenic composition or vaccine of claim 13, which comprises a single unit dose of the genetically attenuated Yersinia pseudotuberculosis cells of claim 1. 15-18. (canceled) 19. The immunogenic composition or vaccine of claim 13, which is formulated for oral administration. 20. The immunogenic composition or vaccine of claim 13, which is formulated for subcutaneous, intradermal, intranasal, or intramuscular administration. 21. The immunogenic composition or vaccine of claim 13, which is formulated for non-oral administration. 22. A method for preventing or treating Y. pestis infection in a mammal, which comprises administering to said mammal at least one genetically attenuated Yersinia pseudotuberculosis cell of claim 1. 23. The method of claim 22, wherein said mammal is a human. 24. A method for preventing or treating Y. pestis infection in a mammal, which comprises administering to said mammal an immunogenic composition of claim 13. 25. The method of claim 24, wherein said mammal is a human.